CRC Research Update — August 27, 2026
Today's colorectal cancer research highlights
Curated CRC research — accessible, accurate, actionable
The CRC Digest
Thursday, August 27, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
TRIAL DATA
Final Analysis of DEEPER Trial Shows No Survival Difference Between Cetuximab and Bevacizumab in RAS/BRAF Wild-Type mCRCThe phase II DEEPER trial found no differences in progression-free survival or overall survival in the per-protocol set when comparing modified-FOLFOXIRI plus cetuximab versus bevacizumab in patients with RAS/BRAF wild-type metastatic colorectal cancer. However, exploratory subgroup analyses showed longer median PFS with cetuximab in patients with RAS/BRAF wild-type and left-sided tumors. (Journal of Clinical Oncology)
-
SCREENING
Blood Test Combining cfDNA Fragmentomics and Methylation Markers Detects Precancerous LesionsA study of 380 CRC patients, 121 individuals with precancerous lesions, and 506 healthy controls found that adding methylation analysis of SEPT9 and HS3ST2 to cfDNA fragmentomic features improved detection of precancerous lesions, a key limitation of blood-based screening. (The ASCO Post)
-
SCREENING
Genetic Risk Stratification Identifies High Adenoma Detection Rates at ColonoscopyA retrospective study of 800 adults from a US health-system biobank who underwent colonoscopy between 2010 and 2025 found that inherited genetic risk may improve yield of adenoma detection and prioritization of colonoscopy in higher-risk individuals. (Gastroenterology and Hepatology Advances)
-
RESEARCH
Fusobacterium nucleatum Detected in 11% of Adenomas, Linked to Immune SignaturesRNA-based detection found Fusobacterium nucleatum in 11% of adenoma tissue samples, with positive patients exhibiting enriched anti-bacterial defense response and immune-related transcriptomic signatures compared to negative patients. (International Journal of Molecular Sciences)
Stay informed and empowered as research continues to advance our understanding of colorectal cancer.
Get CRC research intelligence delivered weekly — free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Every topic in this briefing has a live research dossier — trajectory and evidence — at Signal Bureau.
Got this from a colleague? Subscribe here — we only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe — honored promptly, no login required. · Privacy policy · Manage or delete your data